Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

A New Label for Mifepristone.

Greene MF, Drazen JM.

N Engl J Med. 2016 Jun 9;374(23):2281-2. doi: 10.1056/NEJMe1604462. No abstract available.

2.

Mifepristone label laws and trends in use: recent experiences in four US states.

Sheldon WR, Winikoff B.

Contraception. 2015 Sep;92(3):182-5. doi: 10.1016/j.contraception.2015.06.017. Epub 2015 Jun 23. No abstract available.

PMID:
26116033
3.

From qualified physician to licensed health care professional: the time has come to change mifepristone's label.

Foster AM, Jackson CB, LaRoche KJ, Simmonds K, Taylor D.

Contraception. 2015 Sep;92(3):200-2. doi: 10.1016/j.contraception.2015.06.022. Epub 2015 Jun 30. No abstract available.

PMID:
26134281
4.

Sixteen Years of Overregulation: Time to Unburden Mifeprex.

Mifeprex REMS Study Group, Raymond EG, Blanchard K, Blumenthal PD, Cleland K, Foster AM, Gold M, Grossman D, Pendergast MK, Westhoff CL, Winikoff B.

N Engl J Med. 2017 Feb 23;376(8):790-794. doi: 10.1056/NEJMsb1612526. No abstract available.

PMID:
28225670
5.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Hausknecht RU.

Ann Pharmacother. 2006 Apr;40(4):785-6; author reply 786. Epub 2006 Mar 28. No abstract available.

PMID:
16569806
6.

Mifepristone (Mifeprex) label changes.

[No authors listed]

Med Lett Drugs Ther. 2016 Apr 25;58(1493):55-6. Review. No abstract available.

PMID:
27101211
7.

Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.

Cleland K, Smith N.

Contraception. 2015 Sep;92(3):179-81. doi: 10.1016/j.contraception.2015.06.016. Epub 2015 Jun 18. No abstract available.

PMID:
26093188
8.

Refusal clauses and the weldon amendment: inherently unconstitutional and a dangerous precedent.

Green J.

J Leg Med. 2005 Sep;26(3):401-15. Review. No abstract available.

PMID:
16126638
9.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Svedas E, Maciulaitis R, Stakisaitis D.

Ann Pharmacother. 2006 Apr;40(4):784; author reply 784-5. Epub 2006 Mar 7. No abstract available.

PMID:
16595574
10.

Her accidental legacy.

Rosenberg D.

Newsweek. 2003 Oct 13;142(15):64. No abstract available.

PMID:
16124192
11.

Mifepristone and misoprostol for early abortion.

[No authors listed]

JNMA J Nepal Med Assoc. 2006 Jan-Mar;45(161):I. No abstract available.

PMID:
17160090
12.

Time to misoprostol after mifepristone: still a bone of contention!

Rajaram S, Mehta S, Goel N.

BJOG. 2011 Apr;118(5):629; author reply 629-30. doi: 10.1111/j.1471-0528.2010.02873.x. No abstract available.

13.

Use of misoprostol in pregnancy.

Hale RW, Zinberg S.

N Engl J Med. 2001 Jan 4;344(1):59-60. No abstract available.

PMID:
11136964
14.

Impossible? Outlawing state safety laws for generic drugs.

Glantz LH, Annas GJ.

N Engl J Med. 2011 Aug 25;365(8):681-3. doi: 10.1056/NEJMp1107832. Epub 2011 Aug 10. No abstract available.

15.

Mifepristone for termination of early pregnancy.

[No authors listed]

FDA Consum. 2000 Nov-Dec;34(6):7. No abstract available.

16.

Is there evidence to decrease the approved dose of 600 mg of mifepristone for medical abortion?

Lièvre M, Sitruk-Ware R.

Contraception. 2010 Jun;81(6):553-4. doi: 10.1016/j.contraception.2010.03.001. Epub 2010 Apr 8. No abstract available.

PMID:
20472128
17.

Mifepristone (RU 486).

[No authors listed]

Med Lett Drugs Ther. 2000 Oct 30;42(1091):101-2. No abstract available.

PMID:
11056043
18.

Failed medical termination of twin pregnancy with mifepristone: a case report.

Hausknecht R.

Contraception. 2006 Jan;73(1):109; author reply 109-10. Epub 2005 Sep 9. No abstract available.

PMID:
16371308
19.

Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial.

von Hertzen H, Huong NT, Piaggio G, Bayalag M, Cabezas E, Fang AH, Gemzell-Danielsson K, Hinh ND, Mittal S, Ng EH, Chaturachinda K, Pinter B, Puscasiu L, Savardekar L, Shenoy S, Khomassuridge A, Tuyet HT, Velasco A, Peregoudov A; WHO Research Group on Postovulatory Methods of Fertility Regulation.

BJOG. 2010 Sep;117(10):1186-96. doi: 10.1111/j.1471-0528.2010.02636.x. Epub 2010 Jun 18.

20.

Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.

Shannon CS.

Ann Pharmacother. 2006 Jun;40(6):1215-6; author reply 1216-7. Epub 2006 May 30. No abstract available.

PMID:
16735658

Supplemental Content

Support Center